Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 9/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700744 | 1.00 | NR1H3 (0.49) | NR1H3NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24700182 | 1.00 | NR1H3 (0.49) | NR1H3NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24933194 | 0.85 | CHRM2 (0.38) | NR1H3NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL29795145 | 0.84 | NR1H3 (0.39) | NR1H3NR1H2 | |
| SCHEMBL1189852 | 0.82 | NR1H3 (0.51) | NR1H3NR1H2CCR2USP2SMN1; SMN2 | |
| SCHEMBL25862613 | 0.82 | NR1H3 (0.51) | NR1H3NR1H2CCR2USP2SMN1; SMN2 | |
| SCHEMBL21074964 | 0.82 | NR1H3 (0.51) | NR1H3NR1H2CCR2USP2SMN1; SMN2 | |
| SCHEMBL27059386 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPHSD17B10 | |
| SCHEMBL25949561 | 0.81 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPHSD17B10 | |
| SCHEMBL13932860 | 0.80 | NR1H2 (0.45) | NR1H3NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | NR1H3 449/4885NR1H2 445/4885CHRM2 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.